Frequency and Determinants of Adherence to Oral Anticoagulants in Stroke Patients with Atrial Fibrillation in Clinical Practice

被引:24
作者
Polymeris, Alexandros A. [1 ,2 ]
Traenka, Christopher [1 ,2 ]
Hert, Lisa [1 ,2 ]
Seiffge, David J. [1 ,2 ]
Peters, Nils [1 ,2 ]
De Marchis, Gian Marco [1 ,2 ]
Bonati, Leo H. [1 ,2 ]
Lyrer, Philippe A. [1 ,2 ]
Engelter, Stefan T. [1 ,2 ,3 ,4 ]
机构
[1] Univ Basel Hosp, Stroke Ctr, Petersgraben 4, CH-4031 Basel, Switzerland
[2] Univ Basel Hosp, Neurol, Petersgraben 4, CH-4031 Basel, Switzerland
[3] Univ Basel, Neurorehabil Unit, Basel, Switzerland
[4] Felix Platter Hosp, Univ Ctr Med Aging, Basel, Switzerland
关键词
Atrial fibrillation; Stroke; Non-vitamin K antagonist oral nticoagulants; Adherence; elf-report; Determinants; ACUTE VENOUS THROMBOEMBOLISM; MEDICATION ADHERENCE; ISCHEMIC-STROKE; 1ST YEAR; DABIGATRAN; PERSISTENCE; THERAPY; PREVENTION; NONADHERENCE; RIVAROXABAN;
D O I
10.1159/000450750
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Vitamin K antagonists (VKAs) and non-VKA oral anticoagulants (NOACs) are beneficial in patients with stroke and atrial fibrillation (AF). However, little is known about frequency and determinants of adherence to NOACs/NKAs in clinical practice. Methods: This is a single-center explorative study from the Novel Oral Anticoagulants in Stroke Patients (NOACISP)-LONGTERM registry. We included consecutive AF-stroke patients treated with NOACs/NKAs and followed up for 3-24 months. Adherence was assessed at follow-up using structured interviews and quantified as the proportion of prescribed doses taken (PDT). Outcome measures were (i) full adherence, (ii)>= 95% adherence and (iii) >= 80% adherence (i.e., PDT 100/>= 95/>= 80%). To explore determinants of full adherence, we compared characteristics of fully and non-fully adherent patients. Results: A total of 218 of 251 (86.9%) patients (48% female, mean age 77.9 +/- .1 years, 78% NOACs; 22% VKAs) were eligible for analysis with a median follow-up of 12 months: fully adherent were 78.4% patients (NOACs 77.1%, VKAs 83.3%, p = 0.35), >= 95% adherent were 95.4% and >= 80% adherent were 97.2%. Fully adherent patients took more pills daily (median (interquartile range) 7 (5-10) vs. 6 (4-8), p = 0.039), had more often previous antithrombotic treatment (70.8 vs. 53.2%, p = 0.023), caregiver-assisted medication administration (54.2 vs. 19.1%, p < 0.001) and functional dependency (32.8 vs. 15%, p = 0.011) than non fully adherent patients. Conclusions: Full adherence was frequent. Patients naive to antithrombotics, taking few pills, which they self-administer, were at the highest risk of nonadherence and may benefit most from adherence-enhancing interventions. (C) 2016 S. Karger AG, Basel
引用
收藏
页码:187 / 193
页数:7
相关论文
共 50 条
  • [31] Ischemic Stroke Risk Factors in Patients with Atrial Fibrillation Treated with New Oral Anticoagulants
    Wankowicz, Pawel
    Staszewski, Jacek
    Debiec, Aleksander
    Nowakowska-Kotas, Marta
    Szylinska, Aleksandra
    Rotter, Iwona
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (06) : 1 - 8
  • [32] Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies
    Salmasi, Shahrzad
    Loewen, Peter S.
    Tandun, Rachel
    Andrade, Jason G.
    De Vera, Mary A.
    BMJ OPEN, 2020, 10 (04):
  • [33] Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice
    Ezekowitz, Michael D.
    Spahr, Judy
    Ghosh, Pradeepto
    Corelli, Kathryn
    JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2014, 40 (03) : 261 - 268
  • [34] Novel anticoagulants for stroke prevention in atrial fibrillation
    Baumhaekel, M.
    Schirmer, S. H.
    Boehm, M.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2010, 135 (46) : 2304 - 2308
  • [35] Adherence is an optimal factor for maximizing the effective and safe use of oral anticoagulants in patients with atrial fibrillation
    Yang, So-Young
    Kang, Dong-Won
    Nam, Jin Hyun
    Choi, Eue-Keun
    Lee, Eui-Kyung
    Shin, Ju-Young
    Kwon, Sun-Hong
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [36] Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants
    Morais, Joao
    De Caterina, Raffaele
    CARDIOVASCULAR DRUGS AND THERAPY, 2016, 30 (02) : 201 - 214
  • [37] Preventing stroke in atrial fibrillation patients - clinical utility of oral anticoagulants
    Jhawar, Manish B.
    Flaker, Greg
    JOURNAL OF BLOOD MEDICINE, 2012, 3 : 1 - 13
  • [38] Telemonitoring-based feedback improves adherence to non-vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation
    Desteghe, Lien
    Vijgen, Johan
    Koopman, Pieter
    Dilling-Boer, Dagmara
    Schurmans, Joris
    Dendale, Paul
    Heidbuchel, Hein
    EUROPEAN HEART JOURNAL, 2018, 39 (16) : 1394 - 1403
  • [39] Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants
    João Morais
    Raffaele De Caterina
    Cardiovascular Drugs and Therapy, 2016, 30 : 201 - 214
  • [40] The new oral anticoagulants in atrial fibrillation: an update
    Verheugt, F. W. A.
    NETHERLANDS HEART JOURNAL, 2013, 21 (11) : 480 - 484